Japan Ultrasound Systems Market Size, Share and Forecast Report 2020: Radiant Insights, Inc

GlobalData’s new report, “Japan Ultrasound Systems Market Outlook to 2020”, provides key market data on the Japan Ultrasound Systems market. The report provides value, in millions of US dollars, and volume (in units) and average price data (in US dollars), within market categories – B/W Ultrasound Systems (Portable Systems (B/W) and Stand Alone Systems (B/W)) and Color Ultrasound Systems (Portable Systems and Stand Alone Systems).

The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants, pipeline products, and news and deals related to the Ultrasound Systems market wherever available.

Browse Full Report With TOC @ http://www.radiantinsights.com/research/japan-ultrasound-systems-market-outlook-to-2020

The data in the report is derived from dynamic market forecast models. GlobalData uses capital equipment-based models to estimate and forecast the market size. The objective is to provide information that represents the most up-to-date data of the industry possible.

Capital equipment-based forecasting models are done based on the installed base, replacements and new sales of a specific device/equipment in healthcare facilities such as hospitals, clinics and diagnostic centers. Data for average number of units per facility is used to arrive at the installed base of the capital equipment. Sales for a particular year are arrived at by calculating the replacement units and new units (additional and first-time purchases).

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.

Scope

– Market size for Ultrasound Systems market categories – B/W Ultrasound Systems (Portable Systems (B/W) and Stand Alone Systems (B/W)) and Color Ultrasound Systems (Portable Systems and Stand Alone Systems).

– Annualized market revenues (USD million), volume (units) and average selling price ($) data for each of the market categories. Data is provided from 2005 to 2012 and forecast to 2020.

– 2012 company shares and distribution shares data for the market category.

– Global corporate-level profiles of key companies operating within the Japan Ultrasound Systems market.

– Key players covered include Fujifilm Holdings Corporation, GE Healthcare, Hitachi Medical Corporation, Mindray Medical International Limited, Philips Healthcare, Samsung Medison Co., Ltd., Siemens Healthcare and Toshiba Medical Systems Corporation.

Reasons to buy

– Develop business strategies by identifying the key market segments poised for strong growth in the future.

– Develop market-entry and market expansion strategies.

– Design competition strategies by identifying who-stands-where in the market.

– Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.

– What are the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.

 

About Us

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

For more information visit: Radiant Insights

Contact:

Michelle Thoras

Corporate Sales Specialist, USA

Radiant Insights, Inc

Phone: 1-415-349-0054

Toll Free: 1-888-202-9519

Email: sales@radiantinsights.com

Blog URL: http://www.esorics2010.org/

Advertisements

US Sports Medicine Market Share and Analysis Report: Radiant Insights, Inc

This report focuses on the sports medicine market, which includes implants and arthroscopic capital equipment. The orthopedic sports medicine market has been estimated in this report and covers the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, China and India. The report provides unmet needs, future adoption and compound annual growth rates (CAGR). GlobalData’s analysis shows that while the orthopedics implant market is mature, sports medicine is an area with the potential for significant international growth. With the market, the US remains to be the largest market with the EU to follow and growing.

The APAC region while markedly smaller has a large potential patient population.The top six to seven market leaders continue to dominate the market through technological innovation and investment in establishing strong distribution networks. The major opportunity lies within technological advancement and the clinical trials to prove effectiveness of new techniques.

Read Complete Report with TOC @ http://www.radiantinsights.com/research/medipoint-sports-medicine-us-analysis-and-market-forecasts

The US sports medicine market is a strong and growing market, with prevalence of sports-related injury rising most rapidly among the young and old. The biggest player in sports medicine in the US remains Arthrex, leading with a 21% market share. This company has the strongest brand identity and offers a wide selection of products, which makes it competitive and able to maintain its market share.

Scope

– An overview of sports medicine, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.

– Annualized the US sports medicine market revenue and future forecasts from 2009 to 2011, forecast for 7 years to 2018.

– Investigation of current and future market competition for sports medicine.

– Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.

– Competitor assessment including device approval analysis and device sales forecasts.

– Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.

– Analysis of unmet needs within the market and opportunities for future players.

– Technology trends evaluation to assess strength of pipeline.

– An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.

– Company profiles including business description, financial overview and SWOT analysis.

– Coverage of key market players.

– Strategic assessment of the sports medicine sector through market impact analysis, future market scenario and company analysis.

– Direct quotes from Key Opinion Leaders (KOL) as well as cardiologists

Reasons to buy

– Understand the trends shaping and driving the US sports medicine market.

– Realize device preferences of physicians who have performed the tests already.

– Access market sizing, forecasts and quantified growth opportunities in the US sports medicine market through 2018.

– Quantify candidate patient populations to better design product pricing & launch plans.

– Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.

– Perform benchmarking analysis of growth opportunities against currently marketed products.

– Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.

– Take a comprehensive look at the market’s device pipeline and identify promising, paradigm-shifting products.

– Create an effective counter-strategy to gain a competitive advantage against those currently in the market.

– Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth.

– What’s the next big thing in the US sports medicine market landscape? Identify, understand and capitalize.

About Us

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

For more information visit: Radiant Insights

Contact:

Michelle Thoras

Corporate Sales Specialist, USA

Radiant Insights, Inc

Phone: 1-415-349-0054

Toll Free: 1-888-202-9519

Email: sales@radiantinsights.com

Blog URL: http://www.esorics2010.org/

EVP-6124 (Schizophrenia) Market Size, Trend and Research Report 2022: Radiant Insights, Inc

Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory or visual hallucinations, are often accompanied by fixed, false, and often paranoid beliefs, called delusions. These two features are often combined with learning and cognitive deficits. WHO experts have estimated that roughly 24 million people are affected by schizophrenia worldwide.

While the arrival of atypical antipsychotics has greatly expanded pharmacologic treatment options over the past two decades, the current drug market does not treat the negative and cognitive symptoms that are associated with the disease.

View Full Report with TOC @ http://www.radiantinsights.com/research/evp-6124-schizophrenia-forecast-and-market-analysis-to-2022

GlobalData expects that the growing popularity of long-acting injectable (LAI) antipsychotics, along with the arrival of novel treatments that achieve higher efficacy in negative- and cognitive-predominant patients, will serve to stimulate growth in the marketplace over the forecast period. Country-specific treatment recommendations and policy implementation will be an essential metric for determining future mental health services in the 7MM.

EVP-6124 is a small-molecule a7 nicotinic acetylcholine receptor (nAChR) agonist in co-development by EnVivo and Mitsubishi Tanabe. a7 nAChR stimulation is being researched as a therapy for several neurological conditions, including larger indications such as Alzheimer’s disease and nicotine dependence, following the observation that the target may modulate neuroinflammatory pathways in the brain (Tracey, 2007).

Also known as 3-(1-methylpyrrolidin-2-yl) pyridine, EVP-6124 is an oral medication that penetrates the CNS easily due to its strong lipophilicity. It acts as a co-agonist and sensitizes the ACh receptors so that lesser amounts of ACh can preserve normal cognitive functioning. EVP-6124 is a7-selective and does not activate the a42 subunit, meaning it is non-addictive.

Scope

– Overview of Schizophrenia, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

– Detailed information on EVP-6124 including product description, safety and efficacy profiles as well as a SWOT analysis.

– Sales forecast for EVP-6124 for the top seven countries from 2012 to 2022.

– Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan

Reasons to buy

– Understand and capitalize by identifying products that are most likely to ensure a robust return

– Stay ahead of the competition by understanding the changing competitive landscape for Schizophrenia

– Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

– Make more informed business decisions from insightful and in-depth analysis of EVP-6124 performance

– Obtain sales forecast for EVP-6124 from 2012-2022 in the top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

 

About Us

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

For more information visit: Radiant Insights

Contact:

Michelle Thoras

Corporate Sales Specialist, USA

Radiant Insights, Inc

Phone: 1-415-349-0054

Toll Free: 1-888-202-9519

Email: sales@radiantinsights.com

Blog URL: http://www.esorics2010.org/

Aripiprazole Lauroxil (Schizophrenia) Market Size & Forecast Report 2022: Radiant Insights, Inc

Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory or visual hallucinations, are often accompanied by fixed, false, and often paranoid beliefs, called delusions. These two features are often combined with learning and cognitive deficits.

WHO experts have estimated that roughly 24 million people are affected by schizophrenia worldwide. While the arrival of atypical antipsychotics has greatly expanded pharmacologic treatment options over the past two decades, the current drug market does not treat the negative and cognitive symptoms that are associated with the disease.

GlobalData expects that the growing popularity of long-acting injectable (LAI) antipsychotics, along with the arrival of novel treatments that achieve higher efficacy in negative- and cognitive-predominant patients, will serve to stimulate growth in the marketplace over the forecast period. Country-specific treatment recommendations and policy implementation will be an essential metric for determining future mental health services in the 7MM.

Browse Full Report With TOC @ http://www.radiantinsights.com/research/aripiprazole-lauroxil-schizophrenia-forecast-and-market-analysis-to-2022

Aripiprazole lauroxil is a novel lipid ester prodrug of aripiprazole that utilizes Alkermes’ proprietary LinkeRx technology for once-monthly drug delivery. Once administered IM, aripiprazole lauroxil is converted to aripiprazole, a 5-HT2A antagonist/D2 and 5-HT1A partial agonist that is marketed as Abilify by Otsuka. Alkermes’ aripiprazole lauroxil differs from Otsuka/Lundbeck’s once-monthly formulation of Abilify, called Abilify Depot, in that it is supplied as a suspension and does not require reconstitution prior to administration.

Scope

– Overview of Schizophrenia, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

– Detailed information on Aripiprazole Lauroxil including product description, safety and efficacy profiles as well as a SWOT analysis.

– Sales forecast for Aripiprazole Lauroxil for the top seven countries from 2012 to 2022.

– Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan

Reasons to buy

– Understand and capitalize by identifying products that are most likely to ensure a robust return

– Stay ahead of the competition by understanding the changing competitive landscape for Schizophrenia

– Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

– Make more informed business decisions from insightful and in-depth analysis of Aripiprazole Lauroxil performance

– Obtain sales forecast for Aripiprazole Lauroxil from 2012-2022 in the top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

 

About Us

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

For more information visit: Radiant Insights

Contact:

Michelle Thoras

Corporate Sales Specialist, USA

Radiant Insights, Inc

Phone: 1-415-349-0054

Toll Free: 1-888-202-9519

Email: sales@radiantinsights.com

Blog URL: http://www.esorics2010.org/

Zyprexa (Schizophrenia) Market Share, Trend & Research Report 2022: Radiant Insights, Inc

Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory or visual hallucinations, are often accompanied by fixed, false, and often paranoid beliefs, called delusions. These two features are often combined with learning and cognitive deficits. WHO experts have estimated that roughly 24 million people are affected by schizophrenia worldwide.

While the arrival of atypical antipsychotics has greatly expanded pharmacologic treatment options over the past two decades, the current drug market does not treat the negative and cognitive symptoms that are associated with the disease. GlobalData expects that the growing popularity of long-acting injectable (LAI) antipsychotics, along with the arrival of novel treatments that achieve higher efficacy in negative- and cognitive-predominant patients, will serve to stimulate growth in the marketplace over the forecast period. Country-specific treatment recommendations and policy implementation will be an essential metric for determining future mental health services in the 7MM.

Read Complete Report with TOC @ http://www.radiantinsights.com/research/zyprexa-schizophrenia-forecast-and-market-analysis-to-2022

Olanzapine (Zyprexa; Eli Lilly) is a second-generation antipsychotic that also acts as an antagonist at D2/D3 receptors. But unlike most agents in its class, Zyprexa has a higher relative affinity for serotonin 5-HT2A receptors in comparison to D2/D3 dopaminergic binding sites, a feature that it shares only with clozapine and quetiapine. However, Zyprexa’s activity on M1 and M3 muscarinic and H1 histaminergic receptor sites imply an association with metabolic dysregulation and Zyprexa’s industry reputation has led to tolerability and safety concerns.

Scope

– Overview of Schizophrenia, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

– Detailed information on Zyprexa including product description, safety and efficacy profiles as well as a SWOT analysis.

– Sales forecast for Zyprexa for the top seven countries from 2012 to 2022.

– Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan

Reasons to buy

– Understand and capitalize by identifying products that are most likely to ensure a robust return

– Stay ahead of the competition by understanding the changing competitive landscape for Schizophrenia

– Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

– Make more informed business decisions from insightful and in-depth analysis of Zyprexa performance

– Obtain sales forecast for Zyprexa from 2012-2022 in the top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

 

About Us

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

For more information visit: Radiant Insights

Contact:

Michelle Thoras

Corporate Sales Specialist, USA

Radiant Insights, Inc

Phone: 1-415-349-0054

Toll Free: 1-888-202-9519

Email: sales@radiantinsights.com

Blog URL: http://www.esorics2010.org/

Invega (Schizophrenia) Market Share & Analysis Report 2022: Radiant Insights, Inc

Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory or visual hallucinations, are often accompanied by fixed, false, and often paranoid beliefs, called delusions. These two features are often combined with learning and cognitive deficits. WHO experts have estimated that roughly 24 million people are affected by schizophrenia worldwide. While the arrival of atypical antipsychotics has greatly expanded pharmacologic treatment options over the past two decades, the current drug market does not treat the negative and cognitive symptoms that are associated with the disease.

GlobalData expects that the growing popularity of long-acting injectable (LAI) antipsychotics, along with the arrival of novel treatments that achieve higher efficacy in negative- and cognitive-predominant patients, will serve to stimulate growth in the marketplace over the forecast period. Country-specific treatment recommendations and policy implementation will be an essential metric for determining future mental health services in the 7MM.

View Full Report with TOC @ http://www.radiantinsights.com/research/invega-schizophrenia-forecast-and-market-analysis-to-2022

Invega (paliperidone; Janssen) is the 9-hydroxy metabolite of risperidone and thus shares a similar pharmacologic profile with Risperdal. Invega is a D2 and 5-HT2A antagonist, and though it lacks activity on M1 and M3 muscarinic receptors, it also blocks a1 and a2 adrenergic, and H1 histaminergic receptors.

Scope

– Overview of Schizophrenia, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

– Detailed information on Invega including product description, safety and efficacy profiles as well as a SWOT analysis.

– Sales forecast for Invega for the top seven countries from 2012 to 2022.

– Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan

Reasons to buy

– Understand and capitalize by identifying products that are most likely to ensure a robust return

– Stay ahead of the competition by understanding the changing competitive landscape for Schizophrenia

– Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

– Make more informed business decisions from insightful and in-depth analysis of Invega performance

– Obtain sales forecast for Invega from 2012-2022 in the top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

 

About Us

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

For more information visit: Radiant Insights

Contact:

Michelle Thoras

Corporate Sales Specialist, USA

Radiant Insights, Inc

Phone: 1-415-349-0054

Toll Free: 1-888-202-9519

Email: sales@radiantinsights.com

Blog URL: http://www.esorics2010.org/

Lennox-Gastaut Syndrome For Clinical Trials Market H1, 2015: Radiant Insights, Inc

GlobalData’s clinical trial report, “Lennox-Gastaut Syndrome Global Clinical Trials Review, H1, 2015” provides data on the Lennox-Gastaut Syndrome clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Lennox-Gastaut Syndrome. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe.

The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Lennox-Gastaut Syndrome. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Browse Full Report With TOC @ http://www.radiantinsights.com/research/lennox-gastaut-syndrome-global-clinical-trials-review-h1-2015

Scope

– Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each

– Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type

– Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons To Buy

– Understand the dynamics of a particular indication in a condensed manner

– Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more

– Obtain discontinued trial listing for trials across the globe

– Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

 

About Us

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

For more information visit: Radiant Insights

Contact:

Michelle Thoras

Corporate Sales Specialist, USA

Radiant Insights, Inc

Phone: 1-415-349-0054

Toll Free: 1-888-202-9519

Email: sales@radiantinsights.com

Blog URL: http://www.esorics2010.org/